References
- 1. Kao JH, Chen DS.“Global control of hepatitis B virus infection”. Lancet Infect Dis. 2002; 2: 395.10.1016/S1473-3099(02)00315-8
- 2. http://www.who.int/mediacenter/factsheets/fs204/en/
- 3. Lavanchy D. “Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.” J. Viral Hepat. 2004; 11: 97–107.
- 4. Bedossa P, Carrat F.“Liver biopsy: the best, not the gold standard. J Hepatol. 2009; 50: 1-3.10.1016/j.jhep.2008.10.014
- 5. Xu X, Su Y, Song R et all: “Performance of transient elastography assessing fibrosis of single hepatitis B infection: A systematic review and meta-analysis of a diagnostic test.” Hepatol Int. 2015; 9: 558-66
- 6. Gheorghița V. et al.“Quantitative serum HBsAg in chronic hepatitis B.” Therapeutics, Pharmacology and Clinical Toxicology. 2012; 16 (3): 155-162.
- 7. LiawYF. “Clinical Utility of Hepatitis B surface Antigen Quantitation in Patients with Chronic Hepatitis B: A Review.” Hepatology. 2011; 53: 2121-2129.
- 8. Chevaliez S: “Is HBsAg quantification ready for prime time?” Clin Res Hepatolo Gastroenterol. 2013; 37: 559-63.
- 9. Loggi E, Vitale G., Conti F., Bernardi M. “Chronic hepatitis B: Are we close to a cure?” Digestive and Liver Disease. 2015; 47: 836-841.
- 10. Martinot-PeginouxM et al.: HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis. 2013, 17: 399-412.
- 11. Samant H, Joshi Aet al. “Correlation of QuantitativeHBsAg with Quantitative HBV DNA in Different Phases of Chronic Hepatitis B (CHB) Patients.”J Liver Res Disord Ther. 2016; 1(3).
- 12. Thompson AJ, Nguyen T, Iser D, et al. “Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.” Hepatology. 2010; 51: 1933–1944.10.1002/hep.23571
- 13. Brunetto MR. “A new role for an old marker, HBsAg.” J Hepatol. 2010; 52: 475-477.10.1016/j.jhep.2009.12.020
- 14. European Association for the Study of the Liver. EASL clinical practice guidelines: “Management of chronic hepatitis B virus infection.” J Hepatol. 2017; 67: 370–398.
- 15. Seto WK, Wong DK et al. “High hepatitis B surface antigen levels predict insignigicant fibrosis in hepatitis B e antigen positive chronic hepatitis B.” PLoS One. 2012; 7: e43087
- 16. Zhu HY, Zhang XS. “Relationship between HBV DNA load and levels of serum HBsAg in patients with chronic hepatitis B.” European Review for Medical and Pharmacological Sciences. 2016; 20: 2061-2064.
- 17. Balkan A., Namiduru M.et al. “Are Serum Quantitavie Hepatitis B surface Antigen Levels, Liver Histopathology and Viral Loads related in Chronic Hepatitis B-Infected Patients?” Saudi J Gastronterol. 2016; 22(3) 208-214.
- 18. Hong MZ, Huagn WQ et al. “Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients.” PLoS One. 2014; 9: 1:e87344.
- 19. Günal et al. “Relation between serum quantitative HBsAg, ALT and HBV DNAlevels in HBeAg negative chronic HBV infection.” Turk J Gastroenterol. 2014; 25: 142-6.
- 20. Liu J, Yang H, Lee M.,2 Jen C,1 Utermann R., Lu S.et all. “Serum Levels of Hepatitis B SurfaceAntigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.” Hepatology. 2016; 64: 381-389.